Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.

Weisberg, Ellen; Roesel, Johannes; Furet, Pascal; Bold, Guido; Imbach, Patricia; Flörsheimer, Andreas; Caravatti, Georgio; Jiang, Jingrui; Manley, Paul; Ray, Arghya; Griffin, James D

Weisberg, Ellen; Roesel, Johannes; Furet, Pascal; Bold, Guido; Imbach, Patricia; Flörsheimer, Andreas; Caravatti, Georgio; Jiang, Jingrui; Manley, Paul; Ray, Arghya; Griffin, James D.

Affiliation

Weisberg E; Department of Medical Oncology/Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, MA, USA.

Genes Cancer ; 1(10): 1021-32, 2010 Oct.

Article in En | MEDLINE | ID: mdl-21779428

Key words

AML; FLT3 inhibitor; drug potency; drug resistance; leukemia; neoplasia; structure affinity

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Language: En Journal: Genes Cancer Year: 2010 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Language: En Journal: Genes Cancer Year: 2010 Type: Article Affiliation country: United States